Crizotinib Holds Promise For Lung Cancer, And For Pfizer Oncology
This article was originally published in The Pink Sheet Daily
Executive Summary
The targeted ALK inhibitor is on an accelerated track, with initial Phase I unveiled at ASCO annual meeting and a registration program already under way.
You may also be interested in...
Pfizer Seeks To Salvage Sutent For Lung Cancer
Company hopes development in patient subsets will save expansion plans for top-selling cancer drug.
Pfizer Seeks To Salvage Sutent For Lung Cancer
Company hopes development in patient subsets will save expansion plans for top-selling cancer drug.
FDA Aims For Flexibility In Upcoming Drug/Companion Diagnostic Guidance
FDA is trying to build flexibility into its drug/diagnostic co-development guidance to address variability in how and when therapeutics and companion diagnostics are developed